The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1603
July 27, 2020
View Complete Issue         Table of Contents 2019 
Lumateperone (Caplyta) for Schizophrenia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lumateperone (Caplyta) for Schizophrenia
July 27, 2020 (Issue: 1603)
The FDA has approved lumateperone (Caplyta — Intracellular Therapies), an oral second-generation antipsychotic, for once-daily treatment of schizophrenia in adults. It is the 13th second-generation antipsychotic drug to be approved by the FDA...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lumateperone (Caplyta) for Schizophrenia
Article code: 1603a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.